3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 1
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Pancreatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Lymphoma, Follicular
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Recurrence
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
Rituximab
56
Cyclophosphamide
39
fludarabine
23
fludarabine phosphate
18
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
14
Melphalan
13
Etoposide
12
venetoclax
11
Whole-Body Irradiation
11
Mycophenolic Acid
11
obinutuzumab
10
Vincristine
10
Prednisone
10
Bendamustine Hydrochloride
10
Doxorubicin
9
Cytarabine
9
Cyclosporine
9
Bortezomib
9
Filgrastim
8
pembrolizumab
7
Nivolumab
7
Gemcitabine
7
Busulfan
7
acalabrutinib
6
Tacrolimus
6
Interleukin-2
6
Dexamethasone
6
Carmustine
6
Alemtuzumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Non-Hodgkin
×
durvalumab
×
Clear all
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts